Loading
Immunologist who spent four decades engineering T cells to attack leukaemia and solid tumours.
Philip Greenberg is Head of the Program in Immunology at Fred Hutchinson Cancer Center and a past president of the American Association for Cancer Research (AACR). An immunologist who has spent four decades engineering T cells to attack leukaemia and solid tumours, he pioneered T-cell receptor-engineered cell therapy, including WT1-specific TCR-T for acute myeloid leukaemia after transplant and mesothelin-directed TCR-T for pancreatic cancer. His papers include a Nature Medicine report that T cell receptor gene therapy targeting WT1 prevents acute myeloid leukaemia relapse after transplant and an Advances in Immunology review of the mechanisms by which adoptively transferred T cells recognise and eliminate tumour cells. His work spans TCR-T and CAR-T cell therapy.
| Title | Journal | Year |
|---|---|---|
| T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant | Nature Medicine | 2019 |
| Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells | Advances in Immunology | 1991 |
Shares Mesothelin, TCR-T cell therapy, CAR-T cell therapy.
Shares TCR-T cell therapy, Acute myeloid leukaemia, Pancreatic ductal adenocarcinoma.
Shares TCR-T cell therapy, Pancreatic ductal adenocarcinoma.
Shares American Association for Cancer Research (AACR), Acute myeloid leukaemia.
Shares Fred Hutchinson Cancer Center, Acute myeloid leukaemia.
Shares Fred Hutchinson Cancer Center, TCR-T cell therapy, Acute myeloid leukaemia.
Shares American Association for Cancer Research (AACR), Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/